Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 3, 2002, Pages 201-210

  Meerum Terwogt, Jetske M ^a,b,e   Groenewegen, Gerard ^b,c,e   Pluim, Dick ^a,b,e   Maliepaard, Marc ^a,b,e   Tibben, Matthijs M ^a,b,e   Huisman, Albert ^b,c,e   Ten Bokkel Huinink, Wim W ^a,b,e   Schot, Margaret ^a,b,e   Welbank, Helen ^b,d,e   Voest, Emile E ^b,c,e   Beijnen, Jos H ^a,b,e   Schellens, Jan H ^a,b,e  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d SEQUUS Pharmaceuticals Inc   (United Kingdom)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Liposomal cisplatin; Pharmacokinetics; Phase I study; SPI 77; Stealth liposomes

Indexed keywords

ADENOSINE; CHOLESTEROL; CISPLATIN; CLEMASTINE; DEXAMETHASONE; DNA; GUANINE; LIPOSOME; MITOPODOZIDE; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD SAMPLING; CELL LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA ADDUCT; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DOSAGE FORM; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TISSUE LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOCYTE; MALE; NAUSEA; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; ULTRAFILTRATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAPSULES; CISPLATIN; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PLATINUM; SAFETY; SPECTROPHOTOMETRY, ATOMIC;

EID: 0036186364     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100371     Document Type: Article

References (29)

1. Single and multiple dose pharmacokinetics of SPI-77 (Stealth® liposomal cisplatin) given every 3 weeks in patients with advanced cancer
2. Pharmacokinetics of cisplatin and its monohydrated complex in humans
3. Role of thromboxane receptor on the intracellular accumulation of cis-diamminedichloroplatinum(II) in non-small-cell but not in small-cell lung cancer cell lines
4. +-ATPase on the intracellular accumulation of cis-diamminedichloroplatinum(II) in non-small-cell but not in small-cell lung cancer cell lines
5. Identification and characterization of the blood vessels of solid tumours that are leaky to circulating macromolecules
6. Noncompartmental analysis based on the statistical moment theory
7. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus
8. Pharmacokinetic evidence for the renal absorption of CDDP
9. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma
10. Cisplatin
11. Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair
12. Phase I and pharmacologic study of SPI-77, a novel Stealth® liposomal encapsulated formulation of cisplatin (CDDP)
13. Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry
14. Clinical implications of cisplatin pharmacology
15. 32P-postlabelling assay for the quantification of the major platinum-DNA adducts
16. Two-versus 24-hour infusion of cisplatin: Pharmacokinetic considerations
17. Cisplatin
18. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours
19. Clinical pharmacokinetics of carboplatin
20. Pharmacokinetic evidence for an enterohepatic circulation in a patient treated with cis-dichlorodiammineplatinum(II)
21. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin
22. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin
23. Carboplatin. A preliminary review of its pharmacokinetic properties and therapeutic efficacy in the treatment of cancer
24. The potential of platinum-DNA adduct determination in ex vivo treated tumour fragments for the prediction of sensitivity to cisplatin
25. Pharmacodynamics of cisplatin in human head and neck cancer: Correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo
26. Biological properties of sterically stabilized liposomes
27. Measure of tissue uptake of intravenously injected macromolecules using fluorescence video-microscopy